{"id":"https://openalex.org/W1968485058","doi":"https://doi.org/10.1097/01.aids.0000244200.11006.55","title":"Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically","display_name":"Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically","alternate_titles":[],"publication_year":2006,"publication_date":"2006-09-01","ids":{"openalex":"https://openalex.org/W1968485058","doi":"https://doi.org/10.1097/01.aids.0000244200.11006.55","mag":"1968485058","pmid":"https://pubmed.ncbi.nlm.nih.gov/16954722"},"language":"en","primary_location":{"id":"doi:10.1097/01.aids.0000244200.11006.55","doi":"https://doi.org/10.1097/01.aids.0000244200.11006.55","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.aids.0000244200.11006.55","pdf_url":null,"source":{"id":"https://openalex.org/S20605092","display_name":"AIDS","issn_l":"0269-9370","issn":["0269-9370","1473-5571"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1968485058"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5111543119","display_name":"Mustafa A. Noor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Mustafa A Noor","raw_affiliation_strings":["Discovery and Exploratory Clinical Research, Bristol-Myers Squibb Company, NJ 08543, USA. mustafa.noor@bms.com","to Dr M.A. Noor, Pharmaceutical Research Institute, Bristol-Myers Squibb, PO Box 4500, Princeton, NJ 08543, USA. E-mail: [email\u00a0protected]"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery and Exploratory Clinical Research, Bristol-Myers Squibb Company, NJ 08543, USA. mustafa.noor@bms.com","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"to Dr M.A. Noor, Pharmaceutical Research Institute, Bristol-Myers Squibb, PO Box 4500, Princeton, NJ 08543, USA. E-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066212840","display_name":"Oliver P. Flint","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Oliver P Flint","raw_affiliation_strings":["Discovery Toxicology, USA","to Dr M.A. Noor, Pharmaceutical Research Institute, Bristol-Myers Squibb, PO Box 4500, Princeton, NJ 08543, USA. E-mail: [email\u00a0protected]"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery Toxicology, USA","institution_ids":[]},{"raw_affiliation_string":"to Dr M.A. Noor, Pharmaceutical Research Institute, Bristol-Myers Squibb, PO Box 4500, Princeton, NJ 08543, USA. E-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110557164","display_name":"Jen\u2010Fue Maa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jen-Fue Maa","raw_affiliation_strings":["Virology Medical Affairs Departments, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, New Jersey, USA","to Dr M.A. Noor, Pharmaceutical Research Institute, Bristol-Myers Squibb, PO Box 4500, Princeton, NJ 08543, USA. E-mail: [email\u00a0protected]"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virology Medical Affairs Departments, Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Princeton, New Jersey, USA","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"to Dr M.A. Noor, Pharmaceutical Research Institute, Bristol-Myers Squibb, PO Box 4500, Princeton, NJ 08543, USA. E-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103735839","display_name":"Rex A. Parker","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rex A Parker","raw_affiliation_strings":["Discovery and Exploratory Clinical Research, USA","to Dr M.A. Noor, Pharmaceutical Research Institute, Bristol-Myers Squibb, PO Box 4500, Princeton, NJ 08543, USA. E-mail: [email\u00a0protected]"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Discovery and Exploratory Clinical Research, USA","institution_ids":[]},{"raw_affiliation_string":"to Dr M.A. Noor, Pharmaceutical Research Institute, Bristol-Myers Squibb, PO Box 4500, Princeton, NJ 08543, USA. E-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I4210091812"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5111543119"],"corresponding_institution_ids":["https://openalex.org/I4210091812"],"apc_list":null,"apc_paid":null,"fwci":13.4014,"has_fulltext":false,"cited_by_count":172,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.99328665,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"20","issue":"14","first_page":"1813","last_page":"1821"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11655","display_name":"HIV-related health complications and treatments","score":0.9491999745368958,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11655","display_name":"HIV-related health complications and treatments","score":0.9491999745368958,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.039799999445676804,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ir","display_name":"Ir","score":0.777999997138977},{"id":"https://openalex.org/keywords/ritonavir","display_name":"ritonavir","score":0.9470000267028809},{"id":"https://openalex.org/keywords/lopinavir","display_name":"lopinavir","score":0.9539999961853027},{"id":"https://openalex.org/keywords/hiv-protease-inhibitors","display_name":"HIV protease inhibitors","score":0.9900000095367432},{"id":"https://openalex.org/keywords/insulin-resistance","display_name":"insulin resistance","score":0.9380000233650208},{"id":"https://openalex.org/keywords/insulin-sensitivity","display_name":"insulin sensitivity","score":0.8759999871253967},{"id":"https://openalex.org/keywords/glucose-uptake","display_name":"glucose uptake","score":0.9950000047683716},{"id":"https://openalex.org/keywords/adipocytes","display_name":"adipocytes","score":0.7229999899864197},{"id":"https://openalex.org/keywords/hyperinsulinemic-euglycemic-clamp","display_name":"hyperinsulinemic-euglycemic clamp","score":0.8820000290870667},{"id":"https://openalex.org/keywords/oral-glucose-tolerance","display_name":"oral glucose tolerance","score":0.902999997138977},{"id":"https://openalex.org/keywords/homa-index","display_name":"HOMA index","score":0.796999990940094},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.4790000021457672},{"id":"https://openalex.org/keywords/antiretroviral-therapy-adverse-effects","display_name":"antiretroviral therapy adverse effects","score":0.7680000066757202},{"id":"https://openalex.org/keywords/glucose-metabolism","display_name":"glucose metabolism","score":0.8299999833106995},{"id":"https://openalex.org/keywords/healthy-volunteers","display_name":"healthy volunteers","score":0.39500001072883606},{"id":"https://openalex.org/keywords/cross-over-study","display_name":"cross-over study","score":0.5889999866485596},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.5049999952316284}],"concepts":[{"id":"https://openalex.org/C2779298103","wikidata":"https://www.wikidata.org/wiki/Q422618","display_name":"Ritonavir","level":5,"score":0.9564837217330933},{"id":"https://openalex.org/C2777182164","wikidata":"https://www.wikidata.org/wiki/Q422585","display_name":"Lopinavir","level":5,"score":0.9528141021728516},{"id":"https://openalex.org/C2778414717","wikidata":"https://www.wikidata.org/wiki/Q423467","display_name":"Atazanavir","level":5,"score":0.9439733028411865},{"id":"https://openalex.org/C2781392899","wikidata":"https://www.wikidata.org/wiki/Q422618","display_name":"Lopinavir/ritonavir","level":5,"score":0.7213001847267151},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5569707751274109},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5239120721817017},{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.5213680863380432},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.516082227230072},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.4721512794494629},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4241907000541687},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.34376823902130127},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.12010017037391663},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.08743500709533691},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.07945272326469421},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.0},{"id":"https://openalex.org/C524204448","wikidata":"https://www.wikidata.org/wiki/Q788926","display_name":"Infectious disease (medical specialty)","level":3,"score":0.0},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.0},{"id":"https://openalex.org/C3008058167","wikidata":"https://www.wikidata.org/wiki/Q84263196","display_name":"Coronavirus disease 2019 (COVID-19)","level":4,"score":0.0}],"mesh":[{"descriptor_ui":"D000069446","descriptor_name":"Atazanavir Sulfate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002454","descriptor_name":"Cell Differentiation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004338","descriptor_name":"Drug Combinations","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005947","descriptor_name":"Glucose","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D005951","descriptor_name":"Glucose Tolerance Test","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007333","descriptor_name":"Insulin Resistance","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011744","descriptor_name":"Pyrimidinones","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D011744","descriptor_name":"Pyrimidinones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D015309","descriptor_name":"Glucose Clamp Technique","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D017320","descriptor_name":"HIV Protease Inhibitors","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D017320","descriptor_name":"HIV Protease Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D017667","descriptor_name":"Adipocytes","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D017667","descriptor_name":"Adipocytes","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D018023","descriptor_name":"HIV Seronegativity","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019438","descriptor_name":"Ritonavir","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D019438","descriptor_name":"Ritonavir","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D061466","descriptor_name":"Lopinavir","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/01.aids.0000244200.11006.55","doi":"https://doi.org/10.1097/01.aids.0000244200.11006.55","is_oa":false,"landing_page_url":"https://doi.org/10.1097/01.aids.0000244200.11006.55","pdf_url":null,"source":{"id":"https://openalex.org/S20605092","display_name":"AIDS","issn_l":"0269-9370","issn":["0269-9370","1473-5571"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS","raw_type":"journal-article"},{"id":"pmid:16954722","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16954722","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS (London, England)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W1983657683","https://openalex.org/W1988354903","https://openalex.org/W1989181445","https://openalex.org/W2002147948","https://openalex.org/W2004927761","https://openalex.org/W2010479152","https://openalex.org/W2011910958","https://openalex.org/W2022164197","https://openalex.org/W2025497697","https://openalex.org/W2033756224","https://openalex.org/W2058217770","https://openalex.org/W2062244719","https://openalex.org/W2072177352","https://openalex.org/W2088008322","https://openalex.org/W2104672339","https://openalex.org/W2105912552","https://openalex.org/W2115108568","https://openalex.org/W2124040992","https://openalex.org/W2133795831","https://openalex.org/W2139179624","https://openalex.org/W2160234571","https://openalex.org/W2161139221","https://openalex.org/W2164349191","https://openalex.org/W2166168319","https://openalex.org/W2321486909","https://openalex.org/W4296391115"],"related_works":["https://openalex.org/W2161139221","https://openalex.org/W2359259550","https://openalex.org/W2093847910","https://openalex.org/W2053421106","https://openalex.org/W2027104093","https://openalex.org/W2012955542","https://openalex.org/W3208818910","https://openalex.org/W2011910958","https://openalex.org/W2322411759","https://openalex.org/W2012738913"],"abstract_inverted_index":{"BACKGROUND:":[0],"The":[1,216],"HIV":[2],"protease":[3],"inhibitor":[4],"(PI)":[5],"atazanavir":[6,29,73,142],"does":[7],"not":[8,148,228],"impair":[9],"insulin":[10,18,57,163,171,198,239],"sensitivity":[11,164,172,240],"acutely":[12],"but":[13,227],"ritonavir":[14,36,67,132],"and":[15,49,88,106,131,184,210,237,255],"lopinavir":[16,75,130,144],"induce":[17],"resistance":[19,199],"at":[20,133,205,211],"therapeutic":[21],"concentrations.":[22,135],"OBJECTIVE:":[23],"To":[24],"test":[25],"the":[26,64,84,178,196,219,251],"hypothesis":[27],"that":[28,186],"combined":[30,70,139],"with":[31,71,100,140,165,175,188,208,214,225,229],"a":[32,116],"lower":[33],"dose":[34],"of":[35,66,221],"would":[37],"have":[38],"significantly":[39,127,173,201,224],"less":[40,128],"effect":[41],"on":[42,247],"glucose":[43,90,123,151,222,233,248],"metabolism":[44,249],"than":[45,129],"lopinavir/ritonavir":[46,107,176,226],"in":[47,59,63,94,115,125,235,241],"vitro":[48,126,236],"clinically.":[50],"METHODS:":[51],"Glucose":[52],"uptake":[53,124,234],"was":[54,157],"measured":[55],"following":[56],"stimulation":[58],"differentiated":[60],"human":[61],"adipocytes":[62],"presence":[65],"(2":[68,137],"micromol/l)":[69,138,146],"either":[72,141],"or":[74,143],"(3-30":[76,145],"micromol/l).":[77],"These":[78],"data":[79],"were":[80],"examined":[81],"clinically":[82],"using":[83],"hyperinsulinemic":[85],"euglycemic":[86,154],"clamp":[87],"oral":[89],"tolerance":[91],"testing":[92],"(OGTT)":[93],"26":[95],"healthy":[96,242],"HIV-negative":[97],"men":[98],"treated":[99],"atazanavir/ritonavir":[101,166,189,209,254],"(300/100":[102],"mg":[103,109],"once":[104],"daily)":[105,111],"(400/100":[108],"twice":[110],"for":[112],"10":[113],"days":[114],"randomized":[117],"cross-over":[118],"study.":[119],"RESULTS:":[120],"Atazanavir":[121],"inhibited":[122],"all":[134],"Ritonavir":[136],"did":[147],"further":[149],"inhibit":[150],"uptake.":[152],"During":[153,194],"clamp,":[155],"there":[156],"no":[158],"significant":[159],"change":[160],"from":[161,177,185,203],"baseline":[162,179,204],"(P":[167],"=":[168,192],"0.132),":[169],"while":[170],"decreased":[174],"(-25%;":[180],"P":[181,191],"<":[182],"0.001)":[183],"seen":[187],"(-18%;":[190],"0.023).":[193],"OGTT,":[195],"HOMA":[197],"index":[200],"increased":[202,223],"120":[206],"min":[207,213],"150":[212],"lopinavir/ritonavir.":[215,256],"area":[217],"under":[218],"curve":[220],"atazanavir/ritonavir.":[230],"CONCLUSIONS:":[231],"Both":[232],"clinical":[238],"volunteers":[243],"demonstrate":[244],"differential":[245],"effects":[246],"by":[250],"combination":[252],"PI":[253]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1968485058","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":10},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":7}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
